Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.80 |
| ▸ | ERN1 | O75460 | 9/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12825895 | 0.91 | BRAF (0.79) | BRAFERN1CYP2C9RAF1CYP3A4 | |
| SCHEMBL12826137 | 0.91 | BRAF (0.88) | BRAFERN1CYP2C9RAF1 | |
| SCHEMBL1461862 | 0.89 | BRAF (1.00) | BRAFERN1CYP2C9RAF1 | |
| SCHEMBL14642739 | 0.88 | BRAF (0.65) | BRAFERN1CYP2C9RAF1CYP3A4 | |
| SCHEMBL12826132 | 0.88 | BRAF (0.80) | BRAFERN1CYP2C9RAF1 | |
| SCHEMBL12826222 | 0.86 | BRAF (0.83) | BRAFERN1CYP2C9RAF1 | |
| SCHEMBL14616648 | 0.86 | BRAF (0.76) | BRAFERN1CYP2C9RAF1 | |
| SCHEMBL12826147 | 0.85 | BRAF (0.75) | BRAFERN1 | |
| SCHEMBL12826148 | 0.84 | BRAF (0.76) | BRAFERN1 | |
| SCHEMBL9931540 | 0.84 | BRAF (0.80) | BRAFERN1CYP2C9RAF1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2013-01-17 | — | — | US | disclosed |
| WO-2011025938-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885ERN1 185/4885CYP2C9 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.